LobbyingBelcher Pharmaceuticals lobbying by quarter
Belcher Pharmaceuticals's latest lobbying report covers Q2 2026, at $50K. The four quarters Q4 2025–Q3 2026 total $170K. Its first report covers Q2 2024; the issues it reports most are Government Issues and Pharmacy.
Belcher Pharmaceuticals
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $170K
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2024
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2024 | $0 | 1 |
| Q3 2024 | $0 | 1 |
| Q4 2024 | $0 | 0 |
| Q1 2025 | $0 | 0 |
| Q2 2025 | $0 | 0 |
| Q3 2025 | $0 | 0 |
| Q4 2025 | $60K | 1 |
| Q1 2026 | $60K | 1 |
| Q2 2026 | $50K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Government issues$85K · 3 reports
- Pharmacy$85K · 3 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Food & Drug Administration (FDA)3 reports
- Health & Human Services, Dept of (HHS)3 reports
- HOUSE OF REPRESENTATIVES3 reports
- SENATE3 reports
Firms it paid
| Firm | ||
|---|---|---|
| TSG Advocates DC | $170K | 3 quarters |
| Buchanan Ingersoll & Rooney PC | $0 | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| MARISA HARRILCHAK | Former floor/ staff assistant to Rep. Nancy Pelosi | Q2 2026 |
| BERNARD ROTHSCHILD | With U.S. House of Representatives to 2015 | Q4 2025 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | TSG Advocates DC | $50K |
| 04/17for Q1 | TSG Advocates DC | $60K |
| 01/14for Q4 2025 | TSG Advocates DC | $60K |
| 25/11/14for Q4 2025 | TSG Advocates DC | Under $5,000 |
| 24/10/21for Q3 2024 | Buchanan Ingersoll & Rooney PC | Under $5,000 |
| 24/07/22for Q2 2024 | Buchanan Ingersoll & Rooney PC | Under $5,000 |
| 24/05/31for Q2 2024 | Buchanan Ingersoll & Rooney PC | Under $5,000 |